Lung deflation and cardiovascular structure and function in chronic : obstructive pulmonary disease a randomized controlled trial

American Journal of Respiratory and Critical Care Medicine

Volumn 193, Issue 7, 2016, Pages 717-726

  Stone, Ian S ^a,b   Barnes, Neil C ^b,c   James, Wai Yee ^a   Midwinter, Dawn ^c   Boubertakh, Redha ^b   Follows, Richard ^c   John, Leonette ^a   Petersen, Steffen E ^b  

^a LONDON CHEST HOSPITAL   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Cardiac function; Cardiac magnetic resonance; Chronic obstructive pulmonary disease; Fluticasone furoate vilanterol; Lung hyperinflation

Indexed keywords

FLUTICASONE FUROATE PLUS VILANTEROL; PLACEBO; ANDROSTANE DERIVATIVE; BENZYL ALCOHOL DERIVATIVE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHLOROBENZENE; CORTICOSTEROID; DRUG COMBINATION; FLUTICASONE FUROATE; VILANTEROL;

ADULT; ARTICLE; ATELECTASIS; CARDIAC IMAGING; CARDIOVASCULAR MAGNETIC RESONANCE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEART EJECTION FRACTION; HEART FUNCTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART RIGHT VENTRICLE ENDDIASTOLIC VOLUME; HEART STROKE VOLUME; HUMAN; INSPIRATORY CAPACITY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PULMONARY ARTERY; PULSATILITY INDEX; RANDOMIZED CONTROLLED TRIAL; RESIDUAL VOLUME; SIDE EFFECT; TOTAL LUNG CAPACITY; AGED; CARDIAC MUSCLE; CLINICAL TRIAL; COMPLICATION; DRUG COMBINATION; DRUG EFFECTS; FORCED EXPIRATORY VOLUME; HEART; INHALATIONAL DRUG ADMINISTRATION; LUNG; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PATHOPHYSIOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-2 RECEPTOR AGONISTS; AGED; ANDROSTADIENES; BENZYL ALCOHOLS; BRONCHODILATOR AGENTS; CHLOROBENZENES; CROSS-OVER STUDIES; DRUG COMBINATIONS; FEMALE; FORCED EXPIRATORY VOLUME; HEART; HUMANS; LUNG; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MYOCARDIUM; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84981298126     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201508-1647OC     Document Type: Article

References (33)

1. Stone IS, Barnes NC, Petersen SE. Chronic obstructive pulmonary disease: A modifiable risk factor for cardiovascular disease Heart 2012;98:1055-1062.
2. Han MK, Kazerooni EA, Lynch DA, Liu LX, Murray S, Curtis JL, Criner GJ, Kim V, Bowler RP, Hanania NA, et al.; COPDGene Investigators. Chronic obstructive pulmonary disease exacerbations in the COPDGene study: Associated radiologic phenotypes. Radiology 2011;261:274-282.
3. Casanova C, Cote C, de Torres JP, Aguirre-Jaime A, Marin JM, Pinto-Plata V, Celli BR. Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;171:591-597.
4. Barr RG, Bluemke DA, Ahmed FS, Carr JJ, Enright PL, Hoffman EA, Jiang R, Kawut SM, Kronmal RA, Lima JA, et al. Percent emphysema, airflow obstruction, and impaired left ventricular filling. N Engl J Med 2010;362:217-227.
5. Watz H, Waschki B, Meyer T, Kretschmar G, Kirsten A, Claussen M, Magnussen H. Decreasing cardiac chamber sizes and associated heart dysfunction in COPD: role of hyperinflation. Chest 2010;138: 32-38.
6. Grau M, Barr RG, Lima JA, Hoffman EA, Bluemke DA, Carr JJ, Chahal H, Enright PL, Jain A, Prince MR, et al. Percent emphysema and right ventricular structure and function: The multi-ethnic study of atherosclerosis-lung and multi-ethnic study of atherosclerosis-right ventricle studies. Chest 2013;144:136-144.
7. Jörgensen K, Müller MF, Nel J, Upton RN, Houltz E, Ricksten SE. Reduced intrathoracic blood volume and left and right ventricular dimensions in patients with severe emphysema: An MRI study. Chest 2007;131:1050-1057.
8. Hudsmith LE, Petersen SE, Francis JM, Robson MD, Neubauer S. Normal human left and right ventricular and left atrial dimensions using steady state free precession magnetic resonance imaging. J Cardiovasc Magn Reson 2005;7:775-782.
9. Stone IS, Barnes NC, James W-Y, Midwinter D, Bourbertakh R, Follows R, John L, Petersen SE. The effect of reducing lung hyperinflation with fluticasone furoate/vilanterol on cardiac structure, function and arterial stiffness: A cardiac magnetic resonance study. Am J Respir Crit Care Med 2015;191:A3642.
10. Ceelen F, Hunter RJ, Boubertakh R, Sommer WH, Armbruster M, Schilling RJ, Petersen SE. Effect of atrial fibrillation ablation on myocardial function: insights from cardiac magnetic resonance feature tracking analysis. Int J Cardiovasc Imaging 2013;29: 1807-1817.
11. Sanz J, Kariisa M, Dellegrottaglie S, Prat-González S, Garcia MJ, Fuster V, Rajagopalan S. Evaluation of pulmonary artery stiffness in pulmonary hypertension with cardiac magnetic resonance. JACC Cardiovasc Imaging 2009;2:286-295.
12. Stone IS, John L, Petersen SE, Barnes NC. Reproducibility of arterial stiffness and wave reflections in chronic obstructive pulmonary disease: The contribution of lung hyperinflation and a comparison of techniques. Respir Med 2013;107:1700-1708.
13. Mineo TC, Pompeo E, Rogliani P, Dauri M, Turani F, Bollero P, Magliocchetti N. Effect of lung volume reduction surgery for severe emphysema on right ventricular function. Am J Respir Crit Care Med 2002;165:489-494.
14. O'Donnell DE, Sciurba F, Celli B, Mahler DA, Webb KA, Kalberg CJ, Knobil K. Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD. Chest 2006;130: 647-656.
15. Kaufmann MR, Barr RG, Lima JA, Praestgaard A, Jain A, Tandri H, Bluemke DA, Kawut SM. Right ventricular morphology and the onset of dyspnea: The MESA-right ventricle study. PLoS One 2013;8: e56826.
16. Hsiao SH, Chiou KR. Left atrial expansion index predicts atrial fibrillation in dyspnea. Circ J 2013;77:2712-2721.
17. Kojima T, Kawasaki M, Tanaka R, Ono K, Hirose T, Iwama M, Watanabe T, Noda T, Watanabe S, Takemura G, et al. Left atrial global and regional function in patients with paroxysmal atrial fibrillation has already been impaired before enlargement of left atrium: velocity vector imaging echocardiography study. Eur Heart J Cardiovasc Imaging 2012;13:227-234.
18. Louvaris Z, Kortianou EA, Spetsioti S, Vasilopoulou M, Nasis I, Asimakos A, Zakynthinos S, Vogiatzis I. Intensity of daily physical activity is associated with central hemodynamic and leg muscle oxygen availability in COPD. J Appl Physiol (1985) 2013;115: 794-802.
19. Vanfleteren LE, Kocks JW, Stone IS, Breyer-Kohansal R, Greulich T, Lacedonia D, Buhl R, Fabbri LM, Pavord ID, Barnes N, et al. Moving from the Oslerian paradigm to the post-genomic era: Are asthma and COPD outdated terms Thorax 2014;69:72-79.
20. Sciurba FC, Rogers RM, Keenan RJ, Slivka WA, Gorcsan J III, Ferson PF, Holbert JM, Brown ML, Landreneau RJ. Improvement in pulmonary function and elastic recoil after lung-reduction surgery for diffuse emphysema. N Engl J Med 1996;334:1095-1099.
21. Come CE, Divo MJ, San JoséEstépar R, Sciurba FC, Criner GJ, Marchetti N, Scharf SM, Mosenifar Z, Make BJ, Keller CA, et al.; NETT Research Group. Lung deflation and oxygen pulse in COPD: results from the NETT randomized trial. Respir Med 2012;106: 109-119.
22. Dambrosio M, Cinnella G, Brienza N, Ranieri VM, Giuliani R, Bruno F, Fiore T, Brienza A. Effects of positive end-expiratory pressure on right ventricular function in COPD patients during acute ventilatory failure. Intensive Care Med 1996;22:923-932.
23. Dambrosio M, Fiore G, Brienza N, Cinnella G, Marucci M, Ranieri VM, Greco M, Brienza A. Right ventricular myocardial function in ARF patients. PEEP as a challenge for the right heart. Intensive Care Med 1996;22:772-780.
24. Liu C-Y, Parikh M, Gomes A, Vogel-Claussen J. Chronic obstructive pulmonary disease (COPD) is associated with pulmonary artery stiffness. The MESA COPD study. J Cardiovasc Magn Reson 2013; 15:62.
25. Ertan C, Tarakci N, Ozeke O, Demir AD. Pulmonary artery distensibility in chronic obstructive pulmonary disease. Echocardiography 2013; 30:940-944.
26. Hilde JM, Skjørten I, Grøtta OJ, Hansteen V, Melsom MN, Hisdal J, Humerfelt S, Steine K. Right ventricular dysfunction and remodeling in chronic obstructive pulmonary disease without pulmonary hypertension. J Am Coll Cardiol 2013;62:1103-1111.
27. Peinado VI, Barbera JA, Ramirez J, Gomez FP, Roca J, Jover L, Gimferrer JM, Rodriguez-Roisin R. Endothelial dysfunction in pulmonary arteries of patients with mild COPD. Am J Physiol 1998; 274:L908-L913.
28. Peinado VI, BarberáJA, Abate P, Ramrez J, Roca J, Santos S, Rodriguez-Roisin R. Inflammatory reaction in pulmonary muscular arteries of patients with mild chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;159:1605-1611.
29. Sin DD, Man SF, Marciniuk DD, Ford G, FitzGerald M, Wong E, York E, Mainra RR, Ramesh W, Melenka LS, et al.; ABC (Advair, Biomarkers in COPD) Investigators. The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 177:1207-1214.
30. Barnes NC, Qiu YS, Pavord ID, Parker D, Davis PA, Zhu J, Johnson M, Thomson NC, Jeffery PK; SCO30005 Study Group. Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. Am J Respir Crit Care Med 2006;173:736-743.
31. Milnor WR, Bergel DH, Bargainer JD. Hydraulic power associated with pulmonary blood flow and its relation to heart rate. Circ Res 1966;19: 467-480.
32. Stevens GR, Garcia-Alvarez A, Sahni S, Garcia MJ, Fuster V, Sanz J. RV dysfunction in pulmonary hypertension is independently related to pulmonary artery stiffness. JACC Cardiovasc Imaging 2012;5: 378-387.
33. Ruppel GL. What is the clinical value of lung volumes Respir Care 2012;57:26-35. [Discussion 35-38. ]